The use of opioids for treatment of cancer pain

Bibliography

• Raj SX, Thronaes M, Brunelli C, et al. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer 2014;22:1965-71
   PubMed Web of Science ®Google Scholar
• Breivik H, Cherny N, Collett B, et al. cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-33
   PubMed Web of Science ®Google Scholar
• Koyyalagunta D, Bruera E, Solanki D, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012;15:ES39-58
   PubMed Web of Science ®Google Scholar
• Mercadante S. Cancer pain. Curr Opin Support Palliat Care 2013;7:139-43
   PubMed Web of Science ®Google Scholar
• Mercadante S, Guccione C, Di Fatta S, et al. Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit. Support Care Cancer 2013;21:3287-92
   PubMed Web of Science ®Google Scholar
• Bruera E, Hui D. Palliative care units: the best option for the most distressed. Arch Intern Med 2011;171:1601
   PubMedGoogle Scholar
• Mercadante S, Prestia G, Ranieri M, et al. Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit. Support Care Cancer 2013;21:1853-9
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, dos Santos Pereira JN, Meineke I, et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 2013;86:666-78
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks GW, Kaasa S, et al. Use of opioid analgesic in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:58-68
   PubMed Web of Science ®Google Scholar
• Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management. Clin Biochem 2014;47:1169-87
   PubMed Web of Science ®Google Scholar
• Kane-Gill SL, Rubin EC, Smithburger PL, et al. The cost of opioid-related adverse drug events. J Pain Palliat Care Pharmacother 2014;28:282-93
   PubMedGoogle Scholar
• Fareed A. Hypogonadism and low testosterone levels as a side effect of methadone and buprenorphine. Int J High Risk Behav Addict 2012;1:84-5
   PubMedGoogle Scholar
• Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioidswitching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-41
   PubMed Web of Science ®Google Scholar
• Costantino CM, Gomes I, Stockton SD, et al. Opioid receptor heteromers in analgesia. Expert Rev Mol Med 2012;14:e9
   PubMed Web of Science ®Google Scholar
• Lötsch J. Genetic variability of pain perception and treatment--clinical pharmacological implications. Eur J Clin Pharmacol 2011;67:541-51
   PubMed Web of Science ®Google Scholar
• Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 2013;65:1257-317
   PubMed Web of Science ®Google Scholar
• Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? Br J Anaesth 2011;107:8-18
   PubMed Web of Science ®Google Scholar
• Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 2011;63:1001-19
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-75
   PubMed Web of Science ®Google Scholar
• Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24:479-96
   PubMed Web of Science ®Google Scholar
• Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007;91:199-211
   PubMed Web of Science ®Google Scholar
• Liang DY, Sun Y, Shi XY, et al. Epigenetic regulation of spinal cord gene expression controls opioid-induced hyperalgesia. Mol Pain 2014;10:59
   PubMed Web of Science ®Google Scholar
• Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504-15
   PubMed Web of Science ®Google Scholar
• Davis MP. Evidence from basic research for opioid combinations. Expert Opin Drug Discov 2012;7:165-78
   PubMed Web of Science ®Google Scholar
• Mercadante S, Craig D, Giarratano A. US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs 2012;72:2327-32
   PubMed Web of Science ®Google Scholar
• Pelissier T, Laurido C, Kramer V, et al. Antinociceptive interactions of ketamine with morphine or methadone in mononeuropathic rats. Eur J Pharmacol 2003;477:23-8
   PubMed Web of Science ®Google Scholar
• Mercadante S. Efficacy and safety of dual opioid therapy. Expert Opin Drug Saf 2014;13:1433-6
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Gebbia V. New opioids. J Clin Oncol 2014;32:1671-6
   PubMed Web of Science ®Google Scholar
• Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-6
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187-9
   PubMed Web of Science ®Google Scholar
• Chey WD, Webster L, Sostek M. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387-96
   PubMed Web of Science ®Google Scholar
• Egalet Ltd. Egalet Ltd- Tamper Resistance. Available from: http:/www.egalet.com/technology/technology-overview/tamperresistance/ [Accessed 4 December 2012]
   Google Scholar
• Slatkin NE, Rhiner MI, Gould EM, et al. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. J Opioid Manag 2010;6:181-91
   PubMedGoogle Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72:181-90
   PubMed Web of Science ®Google Scholar
• Stockler MR, Wilcken NR. Why is management of cancer pain still a problem? J Clin Oncol 2012;30:1907-8
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012;30:4373-9
   PubMed Web of Science ®Google Scholar
• Mesgarpour B, Griebler U, Glechner A, et al. Extended-release opioids in the management of cancer pain: a systematic review of efficacy and safety. Eur J Cancer 2013;18:605-16
   Google Scholar
• Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5:2-19
   PubMed Web of Science ®Google Scholar
• Hanna M. The effects of liver impairment on opioids used to relieve pain in cancer patients. Palliat Med 2011;25:604-5
   PubMed Web of Science ®Google Scholar
• Haddad A, Davis M, Lagman R. The pharmacological importance of cytocrome CYP3A4 in the palliation of symptoms: review and recommendations fro avoiding adverse drug reactions. Support Care Cancer 2007;15:251-7
   PubMed Web of Science ®Google Scholar
• Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis 2008;27:5-9
   PubMed Web of Science ®Google Scholar
• Schoder W, De Vry J, Tzeschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive abd neuropathic pain. Eur J Pain 2010;14:814-21
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775-9
   PubMed Web of Science ®Google Scholar
• Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of tapentadol extended release in Japanese and Koren patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013;29:1399-409
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin 2013;29:661-6
   PubMed Web of Science ®Google Scholar
• Linz K, Christoph T, Tschentke TM, et al. Cebranopanol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther 2014;349:535-48
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol 2014; In press
   PubMed Web of Science ®Google Scholar
• Gomes I, Fujita W, Gupta A, et al. Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci USA 2013;110:12072-7
   PubMed Web of Science ®Google Scholar
• Mika J, Popiolek-Barczyk K, Rojewska E, et al. Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain. PLoS One 2014;9:e104420
   PubMed Web of Science ®Google Scholar
• Trevisan G, Rossato MF, Walker CI, et al. A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors. Neuropharmacology 2013;73:261-73
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Rice KC, Maier SF. The toll of opioid-induced glia activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009;30:581-91
   PubMed Web of Science ®Google Scholar
• Poras H, Bonnard E, Dangé E, et al. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem 2014;57:5748-63
   PubMed Web of Science ®Google Scholar
• Viet CT, Dang D, Ono K, et al. Demethylating drugs as novel analgesics for cancer pain. Clin Cancer Res 2014;20:4882-93
   PubMed Web of Science ®Google Scholar